CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2011-02-28): Rifaximin improves cognitive function in hepatic encephalopathy

Drug & Device Development

Rifaximin improves cognitive function in hepatic encephalopathy

Last Updated: 2011-02-28 12:25:15 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Rifaximin improves driving simulator performance in patients with cirrhosis and minimal hepatic encephalopathy, researchers report in the February issue of Gastroenterology.

"The study findings with rifaximin (Xifaxan) are very encouraging because they show that cognitive deficits can be turned back and can also translate into driving skill improvement," Dr. Jasmohan S. Bajaj told Reuters Health by email.

"However, driving simulation was used in this trial, therefore, further research is needed to evaluate whether rifaximin can improve real driving outcomes," he added.

Dr. Bajaj of Virginia Commonwealth University, Richmond, and colleagues note that such patients have cognitive dysfunction that can lead to difficulties in driving. They are at increased risk of driving offenses and have poor insight into their driving skills.

There is evidence that agents including rifaximin can improve cognition, but it's not known whether driving skills also improve.

To investigate, the team randomized 42 patients who were current drivers to rifaximin 550 mg twice daily or to placebo.

Over the 8-week study period, patients given rifaximin made significantly greater improvements in avoiding total driving errors (76% versus 31%). This was also true of speeding (81% versus 33%) and of making illegal turns (62% versus 19%). Collisions weren't significantly affected.

In addition, cognitive performance improved in 91% of the active treatment group compared to 61% of the placebo patients. There was a significant improvement in the psychosocial aspect of the Sickness Impact Profile in the rifaximin group, but no other changes were observed.

The only serum marker alteration seen was a significant increase in the anti-inflammatory cytokine interleukin-10 in the rifaximin group.

This trial, the researchers conclude, "provides a proof-of-concept that improvement in clinically relevant outcomes such as driving performance can be observed with therapy for minimal hepatic encephalopathy using rifaximin."

SOURCE: http://bit.ly/f3zD0U

Gastroenterology 2011;140:478-487.e1.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.